Cytokinetics (KK3A) Stock Price & Analysis
KK3A Stock Chart & Stats
- Day’s Range
- EUR 56.38 - EUR 56.62
- 52-Week Range
- EUR 48.56 - EUR 77.30
- Previous Close
- EUR 57.04
- Volume
- 50
- Average Volume (3M)
- 53
- Market Cap
- EUR 7.81B
- Enterprise Value
- EUR 11.35B
- Total Cash (Recent Filing)
- EUR 1.17B
- Total Debt (Recent Filing)
- EUR 1.27B
- Price to Earnings (P/E)
- ―
- Beta
- 0.14
- Next Earnings
- Nov 04, 2026 (Est.)
- EPS Estimate
- -1.29
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
MYQORZO Commercial Adoption
Rapid growth in dispensed patients, prescriber reach, and product revenue indicates that MYQORZO is gaining early commercial traction. Continued adoption would diversify Cytokinetics beyond collaboration economics and establish a foundation for recurring product revenue as market access expands.
Late-Stage Clinical And Regulatory Progress
Positive pivotal data in non-obstructive HCM could expand aficamten’s addressable patient population beyond its current use case. The planned supplemental filing and existing MAPLE-HCM review create multiple regulatory milestones that may support broader commercialization over the next several quarters.
Strengthened Liquidity
The financing materially increases resources available for commercialization, regulatory filings, and late-stage clinical programs. A larger cash position provides greater flexibility to fund the pipeline and launch activities while reducing the immediate pressure created by the company’s substantial operating expenditures.
Bears Say
Revenue Volatility And Decline
The sharp year-over-year decline shows that reported revenue remains highly dependent on irregular licensing and milestone payments rather than a broad, stable commercial base. Product growth may improve the mix, but near-term results can remain volatile when collaboration milestones do not recur.
Heavy Cash Burn And Persistent Losses
Large recurring cash outflows and sustained net losses require Cytokinetics to fund operations while commercialization and development programs scale. Continued burn can consume liquidity faster than product revenue builds, increasing the importance of disciplined spending and future financing capacity.
Pressured Capital Structure
Negative equity combined with substantial debt indicates limited balance-sheet resilience relative to a stable issuer. This structure can constrain financial flexibility, increase reliance on capital markets, and leave less room to absorb delays in approvals, launches, or revenue growth.
Cytokinetics News
KK3A FAQ
What was Cytokinetics’s price range in the past 12 months?
What is Cytokinetics’s market cap?
When is Cytokinetics’s upcoming earnings report date?
How were Cytokinetics’s earnings last quarter?
Is Cytokinetics overvalued?
Does Cytokinetics pay dividends?
What is Cytokinetics’s EPS estimate?
How many shares outstanding does Cytokinetics have?
What happened to Cytokinetics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cytokinetics?
What is the TipRanks Smart Score and how is it calculated?
Cytokinetics Stock Smart Score
Company Description
Cytokinetics
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Robert I. Blum
- Employees
- 673
- Website
- www.cytokinetics.com
- Address
- 350 Oyster Point Boulevard, South San Francisco, CA, 94080, US
Cytokinetics (KK3A) Earnings & Revenues
KK3A Earnings Call
Earnings Call SentimentPositive
The call conveyed substantial operational and clinical progress: strong early commercial momentum for MYQORZO (rapidly growing prescriptions, rising awareness, >700 prescribers and >1,500 dispensed patients), pivotal ACACIA-HCM positive results with planned sNDA submission, successful European regulatory steps and a $760M financing that boosted cash to ~$1.7B. These strategic and scientific achievements were balanced against near-term financial headwinds including a YOY revenue decline driven by absence of milestone revenue, a wider GAAP net loss ($198.8M), sharply higher SG&A tied to launch costs and upwardly revised 2026 expense guidance. Overall, the operational wins, pivotal data and strong cash position indicate a constructive outlook for growth and future approvals, though investors should expect continued elevated spending as the company scales commercialization and pursues regulatory filings.
View all DE:KK3A earnings summariesKK3A Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 6 | 8 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 6 | 0 | 6 |